- Home
- NXB vs KLRS Comparison
NXB vs KLRS Comparison
Compare NXB & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXB | KLRS |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 44.5M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NXB | KLRS |
|---|---|---|
| Price | $1.45 | $1.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 38.9K | ★ 70.5K |
| Earning Date | 11-21-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,866,298.00 | $165,000.00 |
| Revenue This Year | $41.82 | N/A |
| Revenue Next Year | $29.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.08 | N/A |
| 52 Week Low | $1.40 | $1.78 |
| 52 Week High | $2.57 | $11.88 |
Technical Indicators
Market Signals| Indicator | NXB | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 29.04 | 36.04 |
| Support Level | N/A | N/A |
| Resistance Level | $2.36 | $4.37 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 29.11 | 43.69 |
Price Performance
Historical ComparisonAbout NXB NextBoat Inc. Common Stcok
NextBoat Inc focused on AI-powered technology platform designed to modernize and scale the world-wide pre-owned marine marketplace.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.